WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Stock Short Interest Falls 71.0%

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 11,170 shares, a decline of 71.0% from the September 30th total of 38,536 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 63,773 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of WuXi Biologics (Cayman) to a “hold” rating in a research note on Friday, August 28th. One equities research analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, WuXi Biologics (Cayman) currently has a consensus rating of “Hold”.

Read Our Latest Report on WXXWY

WuXi Biologics (Cayman) Stock Down 1.7%

Shares of OTCMKTS:WXXWY opened at $11.50 on Wednesday. WuXi Biologics has a fifty-two week low of $7.30 and a fifty-two week high of $14.80. The business has a 50-day moving average of $12.93 and a two-hundred day moving average of $10.18.

WuXi Biologics (Cayman) Company Profile

(Get Free Report)

WuXi Biologics (Cayman) Inc is a global contract research, development and manufacturing organization (CRDMO) focused on biologic medicines. The company works with pharmaceutical and biotechnology companies to support the discovery, development and commercial manufacturing of therapies, helping customers advance drug candidates from early research through clinical and commercial production.

Its capabilities include antibody and recombinant protein development, cell-line development, process development, clinical trial material production and large-scale biomanufacturing.

See Also

Receive News & Ratings for WuXi Biologics (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi Biologics (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.